University of Sussex
Browse
1-s2.0-S0264410X13000820-main.pdf (475.93 kB)

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Download (475.93 kB)
journal contribution
posted on 2023-06-09, 14:32 authored by Leonard Both, Ashley C Banyard, Craig van Dolleweerd, Edward WrightEdward Wright, Julian K C Ma, Anthony R Fooks
Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.

History

Publication status

  • Published

File Version

  • Published version

Journal

Vaccine

ISSN

0264410X

Publisher

Elsevier

Issue

12

Volume

31

Page range

1553-1559

Department affiliated with

  • Biochemistry Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2018-08-14

First Open Access (FOA) Date

2018-08-14

First Compliant Deposit (FCD) Date

2018-08-14

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC